gene therapy manufacturing
| 5 min read
After a decade of promise, AAV therapies are now confronting economic, clinical, and regulatory hurdles.
| 2 min read
First commercially available cell culture solution for HEK293 cells and perfusion, optimized for high cell density, intensified processes and perfusion cultures.
| 5 min read
A wave of FDA rejections reveals how CMC issues are becoming a leading barrier to approval in cell and gene therapy development.
| 6 min read
Experts discussed the major hurdles of AAV gene therapy, including immunogenicity, vector design, and AAV variability.
Page 1 of 1 - 4 Total Items
